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The human calcium-sensing receptor gene (CASR) has 8 exons, and localizes to
chromosome 3q. Exons 1A and 1B encode alternative 5′-untranslated regions (UTRs)
that splice to exon 2 encoding the AUG initiation codon. Exons 2–7 encode the CaSR
protein of 1078 amino acids. Promoter P1 has TATA and CCAAT boxes upstream
of exon 1A, and promoter P2 has Sp1/3 motifs at the start site of exon 1B. Exon
1A transcripts from the P1 promoter are reduced in parathyroid tumors and colon
carcinomas. Studies of colon carcinomas and neuroblastomas have emphasized the
importance of epigenetic changes—promoter methylation of the GC-rich P2 promoter,
histone acetylation—as well as involvement of microRNAs in bringing about CASR gene
silencing and reduced CaSR expression. Functional cis-elements in the CASR promoters
responsive to 1,25-dihydroxyvitamin D [1,25(OH)2D], proinflammatory cytokines, and
the transcription factor glial cells missing-2 (GCM2) have been characterized. Reduced
levels of CaSR and reduced responsiveness to active vitamin D in parathyroid neoplasia
and colon carcinoma may blunt the “tumor suppressor” activity of the CaSR. The
hypocalcemia of critically ill patients with burn injury or sepsis is associated with
CASR gene upregulation by TNF-alpha and IL-1beta via kappaB elements, and by
IL-6 via Stat1/3 and Sp1/3 elements in the CASR gene promoters, respectively. The
CASR is transactivated by GCM2—the expression of which is essential for parathyroid
gland development. Hyperactive forms of GCM2 may contribute to later parathyroid
hyperactivity or tumorigenesis. The expression of the CaSR—the calciostat—is regulated
physiologically and pathophysiologically at the gene level.
Keywords: gene, alternative transcripts, transcription, vitamin D, proinflammatory cytokines, glial cells missing-2,
DNA methylation, microRNA
THE CASR GENE
The single-copy CASR gene that maps to human 3q13.3-21 encodes a Class C G protein-coupled
receptor family member (Pollak et al., 1993; Janicic et al., 1995). The T-cell antigen CD86 gene lies
upstream and the cysteine protease inhibitor CSTA gene downstream of the CASR gene and all are
transcribed in the same 5′ to 3′ direction.
The CASR gene has eight exons and spans ∼100-kb (Yun et al., 2007) (Figure 1). Exons 2 to
7 encode the CaSR protein of 1078 aa (GenBank #U20759). Two different polyadenylation signal
sequences within exon 7 may be used, to generate either a short (177-nucleotide) or a long (1304-
nucleotide) 3′-untranslated region (UTR) (Aida et al., 1995; Garrett et al., 1995). Exon 2 encodes
242 nucleotides of the 5′-UTR upstream of the ATG translation initiation codon. Exons 1A and
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FIGURE 1 | Schematic of (A) the CASR gene promoters, (B) the CASR gene exon/intron organization, and (C) CaSR protein. (A) Promoter P1 and P2, gray
bars. Exons 1A and 1B, white bars. Transcription start sites, arrows. CCAAT and TATA boxes, and SP-1 sites driving transcription of exon 1A and 1B, respectively, are
bolded. Cis-acting elements are shown. VDRE, vitamin D response element; κB, kappa-B element responsive to nuclear factor kappa-light-chain-enhancer of
activated B cells; STAT, signal transducer and activator of transcription; GCM, glial cells missing; AP1, activator protein 1; SRE, serum response element. Bolded:
those shown to be functionally active. Not bolded: those predicted but either not functionally active or not yet evaluated. Not all predicted cis-acting elements are
shown. (B) Exon/intron organization of the CASR gene. Exons are drawn to scale introns are not. White bars: mRNA untranslated (exons; 1A, 1B, part of 2, part of 7).
Gray bars: mRNA protein coding (exons; part of 2, 3-6, part of exon 7). ATG: initiation codon. TAA: stop codon. AATAAA: polyadenylation signals. Alternative splicing
of exons 1A and 1B to exon 2 is shown. Asterisk, *: alternative transcript lacking exon 5. Black arrowhead: alternative transcript having additional 30 bases at the
beginning of exon 6. (C) CaSR protein: 1078 amino acid (aa) protein encoded by exons 2-7. Asterisk, *: minus 77 aa encoded by exon 5. Open arrowhead: additional
10 aa encoded by extra 30 bases of alternative RNA transcript. SP, signal peptide; VFT, venus flytrap domain; Cys, cysteine rich domain; ECD, extracellular domain;
TMD, transmembrane domain; ICD, intracellular domain.
1B encode alternative 5′-UTRs that splice to a common segment
encoded by exon 2 (Garrett et al., 1995; Chikatsu et al., 2000).
This organization of exons, conserved around primary protein
domains, is first seen in aquatic vertebrates (Naito et al.,
1998). With diversification from the teleost fishes to tetrapods,
mammals, and primates, the evolutionary changes have been
greatest in the 5′ and 3′ domains. While overall exonic structure
is preserved a striking increase in intron size has occurred
from teleost fish to higher species (Loretz, 2008). Linkage
disequilibrium analysis across the human gene shows a central
haploblock extending from exon 2 to 7 that is distinct from
separate haploblocks for genetic variants in the 5′ and 3′ flanking
regions (Yun et al., 2007).
Thus, the mouse, rat and human genes are organized in a
similar manner. Both rodent genes comprise at least 7 exons and
the translational start site is in exon 2. Alignment of expressed
sequence tags (ESTs) and cloned rodent cDNAs reveal that, just
like the human CASR gene, mouse and rat CASR genes have
at least 2 distinct 5′UTRs (Exons 1A and 1B), suggesting the
presence of at least 2 promoters. The mouse and rat CASR genes
share >85% nucleotide identity (exons and introns) and 40%
with the human CASR. The VDREs and κB elements (see below)
that we have characterized in our studies of the human CASR
gene promoters are conserved in the rodent Casr promoters.
Alternative Transcripts
The CASR gene is highly expressed in the parathyroid gland and
renal tubule (Brown et al., 1993). However, the gene is widely
expressed at lower levels in other tissues, for example in liver
(Canaff et al., 2001), bone (Goltzman and Hendy, 2015) and in
lung, breast, placenta, vasculature and gut (Brennan et al., 2013).
Several alternative transcripts have been identified, raising the
question of their function and regulation of their expression.
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Coexistence of transcripts encoding the same 1078 amino
acid protein in human parathyroid but different 5′ UTRs
suggested alternative splicing (Garrett et al., 1995). Moreover,
the transcripts may have either a short or long 3′ UTR. One
low abundance transcript encodes an additional 10 amino acid
stretch inserted after amino acid 536 in the exodomain (GenBank
#U20760) but does not alter CaSR function (Garrett et al.,
1995). The predominant transcript is 5.4-kb in length, while less
abundant transcripts of 10, 4.8, and 4.2-kb are also found (Garrett
et al., 1995). In human kidney, the 5.4-kb transcript is similarly
predominant with the less abundant 10-kb transcript also present
(Aida et al., 1995).
The human CASR gene has two promoters driving
transcription of alternative 5′ UTR exons (1A and 1B) (Chikatsu
et al., 2000). By northern blot analysis of human parathyroid
adenomas and normal glands, the 5.4 and 10-kb transcripts (see
above) appeared to be exclusive to exon 1A use, while the 4.2-kb
transcripts are derived from either 1A or 1B (Chikatsu et al.,
2000). Real-time PCR (qPCR) analysis of human parathyroid
cells revealed that exon 1B-transcripts were much more highly
expressed than exon 1A-containing transcripts (Mizobuchi et al.,
2009). Transcripts of the 5.4 and 4.2-kb size derive from use
of the two alternative polyadenylation sites in the 3′ UTR tract
(Chikatsu et al., 2000).
An exon 3-deleted CASR transcript has been reported
in thyroid TT cells (Freichel et al., 1996), in placental
cytotrophoblast (Bradbury et al., 1998), and in parathyroid,
thyroid, and kidney (D’Souza-Li et al., 2001). Fusion of exon 2
to exon 4 results in a truncated protein that is poorly expressed
and not trafficked to the cell surface.
In human keratinocytes, an alternatively spliced transcript
lacking exon 5 encodes a variant CaSR with a 77-amino acid in-
frame deletion in the exodomain (Oda et al., 1998). This variant
exerts a dominant negative effect on the full-length protein
making it less responsive to calcium. In addition, the relative
amounts of full-length vs. alternatively spliced transcript decrease
during keratinocyte differentiation (Oda et al., 1998).
Consideration of alternatively spliced forms are of importance
in phenotype evaluation of Casr mice knocked out by deletion
of exon 5 (Ho et al., 1995). In the growth plate (Rodriguez
et al., 2005), skin (Oda et al., 2000) and kidney (Oda
et al., 2000) of the knockout mice, the Casr message lacking
exon 5 is upregulated and compensates for the absence of
the full-length counterpart in bone and cartilage (Rodriguez
et al., 2005). Studies of Casr knockouts in which both full-
length and exon 5 transcripts are deleted have suggested
that the exon 5-deletion model might be hypomorphic with
respect to CaSR actions in the skeleton (Chang et al.,
2008).
Transcriptional Control of the CASR Gene
Regulated CASR gene expression is important in growth and
development (Riccardi et al., 2013), and in normal adult
physiology (Brown, 2013) and in disease pathogenesis (Hannan
and Thakker, 2013). Some of the factors and mechanisms
involved in transactivation of the CASR gene have been identified
(Hendy et al., 2013).
Human CASR transcription is driven by either promoter
P1, with a TATA box at nucleotide −26 and a CCAAT box
at −110 relative to the start site, or P2 with an Sp1/3 site
at the transcriptional start site (Figure 1). The rat and mouse
Casr genes have a similar organization. Both promoters drive
significant levels of basal activity, with promoter P2 being
2.5-fold more active than P1 in most cell types examined as
assessed by transfected promoter-reporter analysis (Canaff and
Hendy, 2002). Also nuclear run-on assays that directly measure
transcripts suggest greater exon 1B relative to exon 1A transcripts
in human thyroid C-cells and renal proximal tubular cells.
The presence of multiple promoters provides the potential for
tissue-specific and/or developmental/temporal-specific regulated
expression from one promoter vs. responsiveness to hormonal
or nutritional stimuli from the other. Evidence for this has
yet to be fully realized for the CASR gene. In fact, from
studies done so far the opposite seems to be the case in
that both promoters respond to active vitamin D, cytokines,
and the parathyroid cell-specific regulator, GCM2 (see below).
However, pathophysiological differences in usage of the CASR
gene promoters have been suggested.
Chikatsu et al. (2000) showed the expression of exon 1A
transcripts driven by the upstream promoter (P1), was decreased
in adenomas, whereas expression of exon 1B transcripts driven
by the (normally stronger) promoter P2 was unchanged. These
results suggested that P1 activity was reduced in parathyroid
adenomas and is qualitatively in agreement with several studies
showing a decrease in CaSR mRNA and protein expression in
parathyroid adenomas relative to normal glands (Kifor et al.,
1996; Farnebo et al., 1997; Gogusev et al., 1997; Cetani et al.,
2000; Corbetta et al., 2000). However, other mechanisms yet to be
identified are likely to contribute to the greater relative decreases
in mRNA and protein expression that are not accounted for
quantitatively by the ∼50% decrease of the apparently weaker
P1 promoter. In a study of colorectal tumors, Kállay et al. (2003)
found exon 1A transcript expression to be greater in the adjacent
“normal” mucosa of colon cancer patients than in the tumor
itself, and a highly significant decrease of exon 1A expression
was found during progression from well-differentiated to poorly
differentiated cancers whereas exon 1B transcript expression
was not significantly altered. More recent studies have found
hypermethylation of promoter P2 that drives the exon 1B
transcripts (Fetahu et al., 2014a) and therefore reduced exon
1B transcript levels would be predicted. Further studies will be
needed to resolve this apparent discrepancy.
Vitamin D
Active vitamin D increases CaSR expression and this has been
documented in several studies in rodents. Parathyroid CaSR
mRNA was reduced by 40% in vitamin D-depleted relative to
replete rats, and 1,25(OH)2D3 administration to vitamin D-
replete rats enhanced parathyroid and kidney CaSRmRNA levels
further (Brown et al., 1996). In another study administration of
1,25(OH)2D3 to rats upregulated renal CaSR mRNA levels in
a dose-and time-dependent manner (Yao et al., 2005). Kidney
CaSR expression (microarray analysis) was downregulated in
VDR null mice relative to their wildtype littermates (Li et al.,
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2003) and likewise (ribonuclease protection assay) forCyp27−/−
mice lacking the 25-hydroxyvitamin D-1α-hydroxylase enzyme
(Canaff et al., 2009a). Injection of 1,25(OH)2D3 in either normal
mice or the Cyp27b1−/− mice caused upregulation of CaSR
expression in parathyroid/thyroid and kidney (Li et al., 2003;
Canaff et al., 2009a). Nuclear run-on assays that measure RNA
transcripts showed that upregulation in thyroid and kidney
cells occurred via gene transcription (Canaff and Hendy, 2002).
Functional vitamin D response elements (VDREs) are present in
both promoters, P1 and P2, of the human CASR gene (Canaff
and Hendy, 2002) and are conserved in the rodent (Hendy et al.,
2013). The VDREs of the CASR are typical in that they consist
of two 6-bp half-sites separated by 3-bp that are bound by the
vitamin D receptor (VDR)-retinoic acid X receptor (RXR) dimer.
However, the VDREs are atypical in that the orientation of the
half-sites is inverted to that which is normally found. VDREs of
this type are found in the 25-hydroxyvitamin D-24-hydroxylase
(CYP24A1) gene.
In the parathyroid gland, the 1,25(OH)2D-upregulated CaSR
makes the gland more responsive to extracellular Ca2+ and PTH
secretion is reduced. The negative action of extracellular Ca2+ on
PTH synthesis and secretion and parathyroid cell proliferation
is reinforced by the active vitamin D metabolite. Impaired
extracellular Ca2+-sensing that drives increased parathyroid cell
proliferation may contribute to parathyroid neoplasia. Somatic
CASRmutations are rare, but parathyroid glands of patients with
primary or severe uremic secondary hyperparathyroidism often
have reduced CaSR expression (Kifor et al., 1996; Cetani et al.,
2000; Corbetta et al., 2000). Thus, reduction in components of the
vitaminD system, active vitaminD ligand either circulating levels
or produced by parathyroid intracrine action, and/or target VDR
levels, that normally decrease PTH synthesis and secretion, could
play an additional role by negating the normal inhibitory effects
of extracellular Ca2+ on PTH via decreased CaSR expression.
The activated kidney CaSR that can act independently of
PTH to directly determine the circulating Ca2+ concentration
(Loupy et al., 2012) inhibits the paracellular uptake of cations
in the cortical thick ascending limb of the distal nephron and
promotes hypercalciuria. Autosomal dominant hypocalcemia
type 1 (ADH1) patients are heterozygous for a gain-of-
function mutant CASR. Treatment of ADH1 patients with active
vitamin D upregulates the oversensitive renal CaSR stimulating
Ca2+ excretion provoking nephrocalcinosis, nephrolithiasis, and
potential renal damage (Pearce et al., 1996; Lienhardt et al.,
2001). For such patients a better treatment option is vitamin
D itself whereby the amount 1,25(OH)2D formed is limited
by product inhibition of the 25-hydroxyvitamin D-1alpha-
hydroxylase enzyme in the proximal tubule (Obermannova et al.,
2016). In some genetic forms of hypercalciuria, altered regulation
of CaSR expression by vitamin D metabolites may be a critical
factor contributing to stone formation. In a genetic stone-
forming rat model of hypercalciuric nephrolithiasis, nephron
VDR levels are elevated, CaSR levels are increased and calcium
reabsorption reduced (Yao et al., 2005; Bai and Favus, 2006).
Alterations of CaSR expression have been implicated not
only in hyperparathyroidism but also other neoplasms. The
CaSR is expressed in human colon epithelium and regulates cell
proliferation and differentiation. Cells of the colon crypt acquire
CaSR expression as they differentiate and migrate toward the
apex of the crypt (Chakrabarty et al., 2005). CaSR expression is
weak or absent in colon carcinomas and is inversely correlated
with differentiation status. Extracellular Ca2+ and 1,25(OH)2D
upregulate CASR transcription and cyclin-dependent kinase
inhibitor expression in the colon and Ca2+ and 1,25(OH)2D
may exert their chemopreventative actions with respect to colon
cancer, in part, through the CaSR (Chakrabarty et al., 2005).
Fetahu et al. (2014b) demonstrated the upregulation of CaSR
expression by 1,25(OH)2D3 in colon cancer cells. This would
be consistent with the active vitamin D metabolite exerting its
antiproliferative, prodifferentiating effects in part by inducing
expression of the tumor suppressor, CaSR.
Vascular calcification occurs during aging and pathologically
in atherosclerosis and chronic kidney disease. There is an inverse
relationship between vascular calcification and expression of the
CaSR (Alam et al., 2009) and maintenance of its expression can
protect against calcification (Molostvov et al., 2015). Treatment
of vascular smooth muscle cells with active vitamin D increases
CaSRmRNA and protein levels (Mary et al., 2015). This would be
consistent with 1,25(OH)2D transactivation of the CASR gene via
its VDREs (Canaff and Hendy, 2002). Treatment with cinacalcet
that enhances sensitivity of the CaSR to Ca2+ promotes CaSR
expression at the cell surface while overall CaSR expression is not
altered (Hénaut et al., 2014). This would be consistent with ligand
induced trafficking of the CaSR to the cell surface (Breitwieser,
2013) and Ca2+ within the normal range and higher having no
marked effect on CASR gene expression (see below for further
detail of potential regulation of CASR by extracellular Ca2+).
Calcium
In addition to 1,25(OH)2D, a potential regulator of CASR
gene expression is extracellular Ca2+ itself. Initial studies did
not find an effect of extracellular Ca2+ on parathyroid gland
or whole kidney CaSR mRNA in the rat in vivo (Rogers
et al., 1995; Brown et al., 1996). A lack of effect on CASR
expression by circulating Ca2+ is perhaps not unexpected in
tissues such as parathyroid gland or kidney, where the CaSR
plays a critical role in Ca2+ homeostasis as a calciostat to sense
small changes in extracellular Ca2+ concentration. Even slight
alterations in the extracellular Ca2+ set-point (the extracellular
Ca2+ concentration at which PTH secretion from the parathyroid
gland or calcium reabsorption across the kidney tubule is half-
maximal) brought about by changes in CaSR synthesis could
disturb overall calcium homeostasis.
CaSR expression did not change in rats having altered
circulating calcium levels as a result of infusion of CaCl2 or
fed vitamin D-deficient diets supplemented with Ca2+ (Rogers
et al., 1995; Brown et al., 1996). In these two studies the
extracellular calcium levels ranged from 0.7 to 1.9mM. However,
potentially, lower or higher Ca+ concentrations could regulate
CaSR expression and perhaps in a tissue-specific manner.
CASR gene transcription was modulated by extracellular Ca+
in studies of transfected CASR promoter-reporter constructs
in human kidney proximal tubule cells and mouse distal
convoluted tubule cells (Canaff, 2004). In both cell types, when
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the concentration of Ca2+ in the media was varied from 1 to
5mM, there was only a slight increase in P1 and P2 promoter
activity. However, there was markedly reduced transcriptional
activity of P1 (by 50%) and P2 (by 30%) in both proximal
and distal convoluted tubule cell types when cultured in a very
low (0.25mM) Ca2+ concentration. Therefore, from normal to
high Ca2+ there was little regulation but from normal to low
calcium there was significant regulation. The results from these
in vitro experiments would be consistent with the lack of obvious
effect of circulating Ca2+ in the in vivo studies referred to
above (Rogers et al., 1995; Brown et al., 1996). In other cells—
differentiated human colon carcinoma cells—upregulation of the
CaSR occurred when the Ca2+ concentration of the culture
medium was increased from very low to normal (Chakrabarty
et al., 2005). Stimulatory effects of Ca2+ and 1,25(OH)2D were
additive for promoter P2 but not for promoter P1 (Chakrabarty
et al., 2005).
What would be the significance in the kidney of a reduced
CaSR expression at low extracellular Ca2+ concentration? A
decrease of CaSR expression in the proximal tubule would
decrease the effect of calcium on the 25-hydroxyvitamin D-
1alpha-hydroxylase activity i.e., the negative impact of Ca2+ in
decreasing enzyme activity would beminimized. In the ascending
limb and distal convoluted tubule, the combination of a reduced
CaSR expression and a low extracellular Ca2+ would favor
maximal Ca2+ reabsorption from the tubule lumen and allow
PTH to stimulate Ca2+ reabsorption without being antagonized
by the CaSR.
The precise pathways by which extracellular Ca2+ might
transactivate the CASR gene are not known. If the extracellular
Ca2+ effect is mediated via the CaSR then a transcription
factor activated by mitogen activated protein kinase (MAPK)
(e.g., Elk1) could be involved. In addition, the involvement of
transcription factors in the reduced expression of the CaSR in
neoplasia of parathyroid and colon, for example, are not known.
In an in vivo murine model of primary hyperparathyroidism in
which cyclin D1 overexpression is targeted to the parathyroid,
expression of the CaSR in the gland is markedly reduced
and correlates with the severity of the hyperparathyroidism
(Kawata et al., 2005). Treatment of the mice with the allosteric
CaSR activator cinacalcet to mimic high levels of extracellular
Ca2+ suppressed serum PTH and Ca2+ and parathyroid cell
proliferation but had no effect on the levels of parathyroid
CaSR mRNA (Imanishi et al., 2011). This reinforces the view
that normal or higher extracellular Ca2+ concentrations do not
significantly modulate parathyroid CaSR expression levels.
Proinflammatory Cytokines
Evidence has accumulated that the increased levels of circulating
cytokines such as IL-1β and IL-6 occurring in conditions of
inflammation could provoke altered systemic Ca2+ homeostasis
by modulating the setting of the calciostat—the expression of
the CaSR. In critically ill patients such as those with sepsis and
major burn injury hypocalcemia is common (Zaloga, 1992; Zivin
et al., 2001; Steele et al., 2013) and in non-acutely ill patients
undergoing surgery (Lepage et al., 1999). Serum IL-1β and IL-
6 levels increase within hours of severe burns and infection
(Kowal-Vern et al., 1994; Klein et al., 1995; Caldwell et al., 1997),
and are inversely related to the falls in serum Ca2+ concentration
(Lind et al., 2000) that may correlate with a poor prognosis (Guo
et al., 1990; Nijsten et al., 1991; Schlüter et al., 1991; Ohzato et al.,
1993; Yamada et al., 1996; Remick et al., 2002). Several factors
such as decreased secretion of PTH and/or resistance to PTH
action in kidney and bone may contribute to the hypocalcemia
(Katz et al., 1992; Klein et al., 1997). In addition, the metabolism
and action of vitamin D can be impaired. Calcitonin precursors
are increased in the circulation of critically ill patients with
sepsis (Lind et al., 2000; Müller et al., 2000; Becker et al., 2004,
2010). Certainly altered PTH secretion and action and vitamin
D metabolism will be most important, whereas calcitonin plays a
minor role in Ca2+ homeostatic control in human.
In patients with rheumatoid arthritis impaired secretion of
PTH is inversely related to the inflammatory activity (Ekenstam
et al., 1990). PTH secretion from bovine parathyroid cells was
suppressed by IL-6 in vitro (Carlstedt et al., 1999) and the same
effect was demonstrated for clinically relevant doses of IL-1β
acting specifically via the IL-1 receptor in bovine parathyroid
tissue slices in vitro with the added observation of upregulation
of CaSR mRNA levels (Nielsen et al., 1997). Parathyroid CaSR
mRNA levels were upregulated in an in vivo sheep model of
burn injury in which increased circulating cytokine levels would
occur (Murphey et al., 2000). Some proinflammatory cytokines
can stimulate (rather than inhibit) the release of PTH. The IL-
8B receptor (CXCR2) was identified in the bovine parathyroid
gland (Angeletti et al., 1998). Cultured bovine parathyroid cells
responded to IL-8 with increases in PTH mRNA levels and PTH
secretion, although any role of altered CaSR expression in these
effects is as yet unknown.
Dysregulated PTH release and altered circulating Ca2+ levels
occurs in septic horses (Toribio et al., 2001; Hurcombe et al.,
2009). Equine parathyroid cells in culture responded to elevations
in extracellular Ca2+ (0.8–2mM) with decreased PTH mRNA
while CaSR mRNA expression was unaltered consistent with
other studies (see above) showing lack of an effect of extracellular
Ca2+ on CaSR expression within this concentration range. IL-
1β acting via the IL-1 receptor decreased both PTH secretion
and increased CaSR mRNA expression (Toribio et al., 2003). In
rats in vivo serum PTH and 1,25(OH)2D decreased significantly
12 h after intraperitoneal (ip) injection of IL-1β, followed by
significantly decreased levels of serum Ca2+ at 15 h (Canaff and
Hendy, 2005). In the same model, decreases in serum PTH and
1,25(OH)2D3 and calcium occurred after ip injection of IL-6
(Canaff et al., 2008b).
The CaSR in part mediates the antiproliferative and
prodifferentiation actions of Ca2+ in colonocytes and can be
considered as a tumor suppressor in the colon. Fetahu et al.
(2014b) showed that in two differentiated colonocyte cell lines
CaSR mRNA and protein levels increased in response to the
cytokines, TNFα, IL-1β, and IL-6. The robust increase of
CaSR expression could represent a defense against inflammation
similar to what had been shown in murine macrophages, in
which lipopolysaccharide-induced TNFα release upregulated
CaSR leading to negative feedback inhibition of synthesis of the
cytokine (Kelly et al., 2011).
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Proinflammatory cytokines, like IL-1β and TNF-α, work
through NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells). NF-κB exists in the cytoplasm of cells in
an inactive form bound to an inhibitor, IκB. Upon receipt of
a signal generated by activation of cytokine receptors, IκB is
phosphorylated, and NF-κB is released from IκB and translocates
to the nucleus to upregulate specific gene transcription via
specific κB response elements. NF-κB is responsible for the
expression of many immune and inflammatory response (and
other) proteins (Ghosh et al., 1998; Baldwin, 2001).
In the rat in vivo IL-1β upregulates parathyroid, thyroid,
and kidney CASR mRNA and protein levels and stimulates
endogenous CASR gene transcription in human thyroid and
kidney cell lines (Canaff and Hendy, 2005). In addition,
we showed that IL-1β and TNF-α upregulate CASR gene
transcription via NF-κB with functional κB response elements
being present in both promoters of the CASR gene (Canaff and
Hendy, 2005).
At the cell surface, IL-6 binds the IL-6 receptor (IL-6R)
consisting of an IL-6 binding α chain (gp80) and the gp130
signal transducer that is shared among the IL-6-related cytokine
subfamily members. IL-6 binding to its receptor activates Janus
kinase (JAK) family members that phosphorylate and activate
signal transducers and activators of transcription (STAT) family
members. The STATS dimerize, translocate to the nucleus
and bind specific gene STAT-response elements activating
transcription (Horvath, 2000; Levy and Darnell, 2002). STAT-1
and STAT-3 are responsible for IL-6 signaling. The JAKS may
also couple to the MAPK pathway to modify the activity of
transcription factors including STATs and others (Heinrich et al.,
2003).
Intraperitoneal injection of IL-6 to rats in vivo caused
decreases in serum PTH, 1,25(OH)2D, and Ca2+ that were
maintained over 24 h (Canaff et al., 2008b). Parathyroid, thyroid
and kidney CaSR mRNA and protein levels were upregulated.
IL-6 increased CASR gene transcription in human thyroid C-
cell and kidney proximal tubule cells in vitro. CASR gene P1
and P2 promoter-driven transcripts were upregulated. Activation
of the MAPK pathway contributed modestly to basal activity
of both P1 and P2 promoters, but it was not involved in a
major way in the IL-6 induction of either of them (Canaff et al.,
2008b). For promoter P1 a STAT1/3 element downstream of the
transcriptional start site accounted for the IL-6 induction. For
promoter P2 that has no STAT elements, IL-6 rapidly promotes
a complex containing both Sp1/3 and STAT1/3 on GC-rich
elements that are clustered at the transcription start site.
The IL-6 administration to rats resulted in a more rapid
decrease in serum PTH, 1,25(OH)2D and Ca2+ levels than that
occurring after IL-1β administration (Canaff and Hendy, 2005;
Canaff et al., 2008b). The quicker response to IL-6 may relate
to this cytokine’s ability to induce rapid changes in mRNA
translation and protein synthesis via the eukaryotic initiation
factor-4F, as has been shown in sensory neurons, for example
(Melemedjian et al., 2010). While IL-6 clearly regulates CASR
gene transcription, uncovering any contribution of the cytokine
at the post-transcriptional level with respect to the resetting of
the calciostat will require further study.
Other Considerations
At sites of injury or infection the inflammatory response
increases circulating proinflammatory cytokines leading to
increased bone resorption. This occurs by enhanced osteocytic
and osteoblastic production of receptor of activatedNF-κB ligand
(RANKL) resulting in increased osteoclastic bone resorption that
releases Ca2+ from the bone (see Klein et al., 2016). One purpose
of the increased extracellular Ca2+ concentration likely relates to
its action as a chemokine on the one hand to recruit macrophages
to sites of cell death and on the other to play a role in amplifying
the inflammatory response via stimulating the assembly of a
cytoplasmic multiprotein complex inflammasome that mediates
proinflammatory cytokine maturation by activation of caspase-1
(see Hendy and Canaff, 2016 for further details).
Therefore, the CaSR in parathyroid gland and kidney executes
its role in Ca2+ homeostasis but it is also expressed in monocytes
and macrophages. This allows the CaSR to play critical roles in
promoting and mediating the inflammatory response to tissue
injury as well as minimizing or limiting these effects via its
role in systemic Ca2+ homeostasis. Whether there is a place
for the use of CaSR allosteric modulators in relevant clinical
areas, for example, in reducing the degree of hypocalcemia in
critically ill patients, remains to be explored. While extracellular
Ca2+ is an activator of the NOD-like receptor family, pyrin
domain-containing protein-3 (NLRP3) inflammasome, influenza
virus infection also activates this particular inflammasome with
resultant production of IL-1β (Allen et al., 2009; Owen and
Gale, 2009; Thomas et al., 2009). This may be relevant to the
observation that ADH1 patients with gain-of-function CASR
mutations often become symptomatic (e.g., with seizures) during
periods of intercurrent illness (Hendy et al., 2009). Enhanced
expression of the activated CaSR by the increased circulating
IL-1β cytokine would result in extracellular Ca2+ levels to drop
further to symptomatic levels.
An additional pathological role for Ca2+, CaSR,
proinflammatory cytokines, and obesity has been suggested
(Villarroel et al., 2014). It is proposed that Ca2+ activation
of the CaSR in white adipose tissue preadipocytes increases
proinflammatory cytokine production, proliferation and
differentiation but decreased liped accumulation and adipose
tissue dysfunction (Cifuentes et al., 2012). The obesity associated
cytokines like TNF-α and IL-1β increase adipocyte CaSR
expression (Cifuentes et al., 2010) by releasing NFκB to
translocate to the nucleus and activate the CASR gene at κB
response elements in its promoters (Canaff and Hendy, 2005).
This represents a positive feed forward loop.
Glial Cells Missing-2
In Drosophila the transcription factor glial cells missing (GCM)
acts as a developmental binary switch between glia and
neurones. In mammals, there are two orthologs GCM1/GCMA
and GCM2/GCMB critical for parathyroid and placental
development, respectively (Kim et al., 1998; Kammerer et al.,
1999; Kanemura et al., 1999). The five exons of the GCM2 gene
(OMIM# 603716) on chromosome 6p24.2 encode a protein of
506 amino acids. GCM2 is expressed in the PTH-secreting cells
of the parathyroid glands and is critical for their development
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in terrestrial vertebrates, and continues to be expressed in the
adult (Günther et al., 2000;Maret et al., 2004; Okabe andGraham,
2004; Liu et al., 2007). FromNH2 to COOH termini of the GCM2
protein there is a DNA-binding domain, transactivation domain
1, an inhibitory domain, and transactivation domain 2.
Homozygous or heterozygous inactivating mutations occur
in familial isolated hypoparathyroidism (FIH) inherited in
an autosomal recessive or dominant manner, respectively
(Hendy and Cole, 2015). Autosomal recessive mutations include
missense, stop, frameshift, and gene deletion, (e.g., Ding et al.,
2001; Baumber et al., 2005; Thomée et al., 2005; Bowl et al.,
2010; Tomar et al., 2010; Doyle et al., 2012). Autosomal dominant
mutations include missense and single-nucleotide deletion (e.g.,
Mannstadt et al., 2008; Canaff et al., 2009b; Mirczuk et al.,
2010; Yi et al., 2012). In vitro functional studies of some of
these mutants have demonstrated loss of GCM response element
binding and/transcriptional activity in the case of recessive
mutations, as well as the ability of dominant mutants to inhibit
activity of wild-type GCM2when the two are transfected together
into cells (Mannstadt et al., 2008; Canaff et al., 2009b; Mirczuk
et al., 2010).
Genetic defects affecting GCM2 are rare in FIH: a study of 20
unrelated FIH cases (10 familial and 10 sporadic) found several
polymorphic variants, but did not find GCM2 mutations that
segregated with the disease and/or led to loss of function (Maret
et al., 2008).
The CaSR is an early parathyroid differentiation marker (Liu
et al., 2007). Absence or reduction of parathyroid GCM2, as in
mice null for Gcm2 (Günther et al., 2000) or in cultured human
parathyroid cells treated with GCM2 siRNA (Mizobuchi et al.,
2009), correlates with lack or decreased expression of the CaSR.
GCM2 transactivates the CASR gene via GCM response elements
in promoters P1 and P2 (Canaff et al., 2008a, 2009b). Thus,
GCM2 and CaSR are mechanistically linked with respect to the
development of the evolutionarily related parathyroid glands (in
terrestrial vertebrates) and gills (in fish) (Okabe and Graham,
2004).
v-maf musculo-aponeurotic fibrosarcoma oncogene homolog
B (MafB), a transcriptional activator, is present in developing and
mature parathyroid glands (Kamitani-Kawamoto et al., 2011).
MafB acts downstream of GCM2 and ensures that the developing
parathyroid glands properly localize between the thyroid and the
thymus (Kamitani-Kawamoto et al., 2011). GCM2 associates with
MafB to synergistically activate PTH gene expression (Kawahara
et al., 2010; Kamitani-Kawamoto et al., 2011).
Haploinsufficiency of the dual zinc-finger transcription factor,
GATA3, results in the congenital hypoparathyroidism-deafness-
renal dysplasia (HDR) syndrome (Ali et al., 2007). Gata3
knockout mouse embryos lack Gcm2 expression and have gross
defects in the third and fourth pharyngeal pouches including
absent parathyroid-thymus primordia (Grigorieva et al., 2010).
GATA3 transactivates the GCM2 gene by binding specifically to
a double-GATA-motif within the GCM2 promoter. In addition,
GATA3 cooperates with GCM2 and MafB to activate PTH gene
expression by interacting with the ubiquitous specificity protein-
1 (SP1) transcription factor (Han et al., 2015). Thus, GATA3,
GCM2 and MafB are part of a critical transcriptional cascade in
the parathyroid morphogenesis and CaSR and PTH expression
pathway (Grigorieva and Thakker, 2011; Han et al., 2015).
The persistance of GCM2 expression in the adult parathyroid
raises the question of whether its overactivity or reduced
expression could play a role in the development of parathyroid
hyperfunction or tumorigenesis. In support of the first notion,
increased expression of GCM2 has been noted in some
adenomas of primary parathyroid patients (Kebebew et al.,
2004). Furthermore, the allele frequency of a common Y282D
polymorphism is significantly higher in Italian cohorts of
primary hyperparathyroid patients than in normal individuals
and the 282D variant exhibits higher activity on a GCM element
promoter than Y282 (D’Agruma et al., 2014). In support of the
second supposition, reduced levels of GCM2 mRNA have been
reported in adenomatous tissue from some patients with primary
hyperparathyroidism (Correa et al., 2002). This may contribute
to the reduced CaSR expression commonly found in these tumors
that might itself contribute to dysregulated control of parathyroid
cell proliferation.
CASR Expression and Kidney Stones
Evidence has been provided that CaSR polymorphisms such
as R990G can increase the susceptibility to hypercalciuria
and urolithiasis (Liu et al., 2015). But single nucleotide
polymorphisms (SNPs) within the regulatory regions of the
CASR gene have also been associated with kidney stone risk,
for example, in primary hyperparathyroidism (Vezzoli et al.,
2011). A comparison of idiopathic calcium stone formers and
healthy controls revealed one SNP (rs6776158 [A>G]) located in
the CASR P1 promoter that was associated with nephrolithiasis
(Vezzoli et al., 2013). Sr2+ handling has been proposed to be
a mirror of Ca2+ metabolism and reduced Sr2+ excretion after
an oral load was observed in GG homozygous stone formers.
Activity of the G allele CASR P1 promoter-luciferase reporter was
lower (than the A allele promoter) in cell transfection studies
and CaSR mRNA levels were lower in kidney medulla samples in
GG homozygous individuals than A allele carriers (Vezzoli et al.,
2013). Therefore, the minor allele at rs6776158 may predispose
to calcium stones by decreasing transcriptional activity of the
CASR P1 promoter and CaSR expression in kidney tubules.
Claudin-14 is a member of a superfamily of proteins that regulate
paracellular transport of ions and small solutes at epithelial tight
junctions. A mechanistic link between CASR gene activity was
suggested by the finding that claudin-14 mRNA levels were lower
in the CASR rs6776158 GG homozygous subjects Therefore, in
these cases the predisposition to calcium nephrolithiasis is by a
mechanism independent of hypercalciuria (Vezzoli et al., 2013).
This hypothesis received further support by a comparison of
another CASR gene regulatory SNP and R990G with respect to
stone risk in primary hyperparathyroidism (Vezzoli et al., 2015).
In a genome-wide association study (GWAS) of Icelandic
kidney stone cases a suggestive association of (rs7627468 [A]) in a
CASR intron1 regulatory region was found in a large population
set (Oddsson et al., 2015). A strong association was found for a
polymorphism (rs199565725 [delAC]) in intron 1 of the CLDN14
gene encoding claudin-14 that might mediate a decrease in
CLDN14 gene function. These data reinforced that of the same
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group in an earlier study (Thorleifsson et al., 2009). The authors
observed uncorrelated genome-wide significant association of
variants at the CASR locus that also influence biochemical
traits, serum total and ionized calcium, for example, but do not
associate with the kidney stone disease. This implies that the risk
is not mediated solely through the serum level of calcium or other
biochemical trait (Oddsson et al., 2015), and provides further
indirect support for the CASR directed Claudin-14 mechanism
(Gong et al., 2012; Gong and Hou, 2014; Toka et al., 2015;
Riccardi and Valenti, 2016).
CASR and Epigenetic Modification
Altered CaSR expression occurs in benign and malignant tumors
suggesting it as either a tumor suppressor or oncogene. The
epigenetic inactivation of the CASR may underlie the reduced
CaSR expression in some cancers. The CASR P2 promoter that
is GC-rich, is methylated to a greater extent in colorectal tumors
relative to adjacent mucosa and this correlates with the reduced
CaSR levels in the tumors (Hizaki et al., 2011; Fetahu et al.,
2014a). Use of histone deacetylase inhibitors in colon cancer
cell lines most of which poorly express CaSR has implicated the
involvement of H3K9 deacetylation in the silencing of CASR in
colorectal cancer (Hizaki et al., 2011; Fetahu et al., 2014a). Similar
findings with respect to methylation of the CASR P2 promoter
were reported for unfavorable neuroblastomas in which CaSR is
barely detectable (Casalà et al., 2013). In addition, monosomy
of chromosome 3 where CASR resides was found in the vast
majority of primary neuroblastic tumors of all types (Casalà
et al., 2013). Hence the CASR is silenced by both genetic and
epigenetic means in these tumors. However, no evidence has
been found of loss of CASR alleles (Farnebo et al., 1997) or
CASR gene methylation being responsible for the reduced CaSR
levels in primary and secondary hyperparathyroidism (Hofman-
Bang et al., 2012; Sulaiman et al., 2013; Varshney et al., 2013).
Moreover, the molecular mechanisms underlying the enhanced
expression of CaSR in breast and prostate tumors that implicates
an oncogenic role for CaSR in these tissues have yet to be
deciphered (Tennakoon et al., 2016).
CaSR And MicroRNAs
MicroRNAs (miRNAs) are short non-coding RNAs that function
in RNA silencing and post-transcriptional regulation of gene
expression. A further cause of silencing of the CaSR in colorectal
tumors has been proposed to be increased expression of miR-
135b and miR-146b that are considered to be oncogenic (Fetahu
et al., 2016). In colon cancer cell lines other miRNAs, miR-
21, miR-145, and miR-135a, are inversely correlated with CaSR
expression (Singh and Chakrabarty, 2013; Singh et al., 2013).
Altered expression of miRNAs may well have an important role
in development of parathyroid tumors and miRNAs have been
implicated in parathyroid function. Dicer-dependent maturation
of parathyroid miRNAs is responsible for the dysregulated
control of PTH secretion in a uremic mouse model of secondary
hyperparathyroidism (Shilo et al., 2015). However, specific
miRNAs that directly affect parathyroid CaSR expression have yet
to be identified.
PERSPECTIVES AND CONCLUSIONS
The CaSR is expressed in the central nervous system and the roles
it may play in the brain are being explored (Ruat and Traiffort,
2013). It will be important in future to understand the precise
mechanisms underlying the postnatal upregulation of the brain
CaSR during development and whether altered regulation of the
CaSR plays a role in some cases of epilepsy. Within neurons the
CaSR may play a role in susceptibility to Alzheimer’s Disease
(AD) and its progression (Chiarini et al., 2016). CASR expression
may be altered in AD as it is regulated by the same transcription
factors (e.g., SP1/3, AP1, STAT1/3, NF-κB, TFIID) already known
to modulate other AD-regulated genes (Chiarini et al., 2016).
However, this has yet to be directly evaluated.
The blood-brain barrier defends extracellular Ca2+ in the
brain from changes in serum Ca2+ and at rest brain extracellular
Ca2+ is maintained at 1.1mM. During neuronal activity
extracellular Ca2+ can fall sharply as Ca2+ moves to intracellular
compartments. Following action potentials, Ca2+ can fall as
low as 0.3mM in the synaptic cleft (Jones and Smith, 2016).
Any potential changes on CASR gene expression and their
consequences have yet to be examined.
Further insights to those described in the present review,
can be anticipated with respect to identification of additional
transcriptional factors and their cis-elements in the CASR gene
promoters, epigenetic changes involving direct methylation of
the CASR DNA as well as histone modifications and chromatin
remodeling. The direct effect of miRNAs on degradation of CaSR
mRNA or inhibition of its translation will become clearer.
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